Maravai LifeSciences (MRVI) and Its Peers Financial Contrast

Maravai LifeSciences (NASDAQ:MRVI) is one of 109 public companies in the “Life Sciences Tools & Services” industry, but how does it contrast to its peers? We will compare Maravai LifeSciences to related businesses based on the strength of its analyst recommendations, dividends, profitability, institutional ownership, risk, valuation and earnings.

Institutional & Insider Ownership

50.2% of Maravai LifeSciences shares are held by institutional investors. Comparatively, 54.3% of shares of all “Life Sciences Tools & Services” companies are held by institutional investors. 2.5% of Maravai LifeSciences shares are held by company insiders. Comparatively, 15.2% of shares of all “Life Sciences Tools & Services” companies are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Volatility and Risk

Maravai LifeSciences has a beta of 0.61, indicating that its share price is 39% less volatile than the S&P 500. Comparatively, Maravai LifeSciences’ peers have a beta of 0.94, indicating that their average share price is 6% less volatile than the S&P 500.

Analyst Ratings

This is a breakdown of current ratings and target prices for Maravai LifeSciences and its peers, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Maravai LifeSciences	1	1	2	1	2.60
Maravai LifeSciences Competitors	957	3183	5516	178	2.50

Maravai LifeSciences presently has a consensus target price of $7.38, indicating a potential downside of 6.17%. As a group, “Life Sciences Tools & Services” companies have a potential downside of 2.05%. Given Maravai LifeSciences’ peers higher probable upside, analysts plainly believe Maravai LifeSciences has less favorable growth aspects than its peers.

Profitability

This table compares Maravai LifeSciences and its peers’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Maravai LifeSciences	-30.83%	-12.44%	-6.66%
Maravai LifeSciences Competitors	-539.78%	77.25%	-13.56%

Valuation & Earnings

This table compares Maravai LifeSciences and its peers gross revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Maravai LifeSciences	$185.74 million	-$130.77 million	-18.28
Maravai LifeSciences Competitors	$2.28 billion	$55.88 billion	-7.74

Maravai LifeSciences’ peers have higher revenue and earnings than Maravai LifeSciences. Maravai LifeSciences is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.

Summary

Maravai LifeSciences peers beat Maravai LifeSciences on 9 of the 13 factors compared.

About Maravai LifeSciences

Maravai LifeSciences provides products and services used by biotechnology and pharmaceutical companies in the development and production of therapeutics, vaccines, and other biologic products. Its offerings include specialized nucleic acid materials and analytical testing services that support research, manufacturing, and quality control. Through TriLink BioTechnologies, the company supplies modified nucleotides, custom RNA and DNA, and related materials used in applications such as messenger RNA research and production.